The invention belongs to the field of anti-
arteriosclerosis drugs, and particularly relates to application of a
carbonic anhydrase inhibitor to preparation of the anti-
arteriosclerosis drugs. The study finds for the first time that
carbonic anhydrase 1 (CA1) is highly expressed in
arteriosclerosis calcified tissue, and CA1 is related to
vascular smooth muscle calcification and affects
cell proliferation and
apoptosis. Methazolamide, the inhibitor of CA1, can significantly reduce the progression of atherosclerosis and inhibit atherosclerotic
inflammatory factors. The results suggest that
calcification plays an important role in atherosclerosis, and CA1-dominated
calcification promotes the course of the atherosclerosis. Methazolamide has a potential
therapeutic effect on the atherosclerosisby inhibiting expression of CA1. The findings not only further explain the
close relationship between the atherosclerosis and the calcification, but also explore the calcification mechanism of the atherosclerosis, and further prove that inhibition of the calcification is a key point in the treatment of the atherosclerosis. The application of the
carbonic anhydrase inhibitor to the preparation of the anti-arteriosclerosis drugs provides new ideas for the treatment of the atherosclerosis.